Replies to post #860 on Trius Therapeutics, Inc. (TSRX)

[LongRun8]

I know it's a murky situation for sure.

I asked Trius IR about not tendering shares and what would happen. This is what I got back.

Thank you for your inquiry.
If you do not tender your shares and the deal goes through you will receive the $13.50 per share and the CVR.
More information may be found at investor.triusrx.com/sec.cfm


Hillary Theakston
Investor Relations for Trius
[e-mail]
[phone] x440

So it DOES look like we'll be paid out those shares at the current deal's specifics; which is nice.